RxDoctor Payments Data

Amber Scoggins

Family · Burlington, NCNPI 1851057111

Payments from drug & device makers

$3,562in general payments, 2019–2025

Across 194 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$399
  • Merck$388
  • Esperion Therapeutics, Inc.$301
  • AstraZeneca$245
  • Boehringer Ingelheim$189
  • Johnson & Johnson$173
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$3,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,562 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol11$9,636
LinzessLinaclotide12$7,102
Albuterol Sulfate HfaAlbuterol Sulfate19$696
Rosuvastatin Calcium52$506
Atorvastatin Calcium34$369
Omeprazole16$304
ClopidogrelClopidogrel Bisulfate19$280
Metoprolol Succinate28$245
Losartan Potassium20$236
Montelukast Sodium19$221
Celecoxib11$211
Trazodone Hcl17$196
Levothyroxine Sodium29$196
Gabapentin18$195
Pantoprazole Sodium28$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$245$9,63611 claims
AbbVieLinzess$19$7,10212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →